NASDAQ$EPIX
Essa Pharma Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported financial results for the fiscal first quarter ended December 31, 2022.
ESSA Pharma reported its financial results for the fiscal first quarter ended December 31, 2022. The company's cash position is expected to be sufficient to fund current and planned operations through 2025.
- Advanced studies of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) in patients with mCRPC naïve to second generation anti-androgens expected to complete in 1H2023.
- Phase 2 randomized study in the same patient population to be initiated shortly thereafter.
- Cash runway expected to fund operations and clinical programs through 2025.
Headline financials
Revenue & EPS history
Essa Pharma · Revenue · Quarterly
$0
Forward guidance
The company expects to complete the Phase 1 EPI-7386 combination study with enzalutamide in the first half of 2023 and initiate the Phase 2 randomized study shortly thereafter. The company's cash position is expected to be sufficient to fund current and planned operations through 2025.
Tailwinds
- Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023.
- Initiation of the randomized Phase 2 study shortly thereafter.
- Ongoing Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients.
- Cash runway expected to fund operations and clinical programs through 2025.
- Advancing studies of EPI-7386 in patients with metastatic castration-resistant prostate cancer.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports
-0.3%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-3.2%
Avg return
30 days after
39%
13 / 33 earnings
Positive
+46.0%
Q1 2021
Best reaction
-34.9%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.0% | +0.0% | -89.5% | |
| Q2 2025 | +1.2% | -1.8% | -1.2% | |
| Q1 2025 | -3.0% | +3.6% | -2.4% | |
| Q4 2024 | -1.2% | -1.8% | +7.4% | |
| Q3 2024 | -5.5% | -2.6% | +22.9% | |
| Q2 2024 | +4.6% | +4.9% | -21.3% | |
| Q1 2024 | +2.5% | -5.4% | -10.0% | |
| Q4 2023 | +3.2% | +16.4% | +58.7% | |
| Q3 2023 | -2.8% | -4.5% | -5.6% | |
| Q2 2023 | -4.1% | +2.7% | +8.6% | |
| Q1 2023 | +2.1% | +0.3% | -2.4% | |
| Q4 2022 | -6.9% | — | — | |
| Q3 2022 | +3.1% | — | — | |
| Q2 2022 | +5.4% | — | — | |
| Q1 2022 | +1.4% | — | — | |
| Q4 2021 | +0.6% | — | — | |
| Q3 2021 | -34.9% | — | — | |
| Q2 2021 | -1.8% | — | — | |
| Q1 2021 | +46.0% | — | — | |
| Q4 2020 | +8.6% | — | — | |
| Q1 2020 | +0.0% | — | — | |
| Q4 2019 | -0.2% | — | — | |
| Q1 2019 | +3.2% | — | — | |
| Q2 2019 | -8.7% | — | — | |
| Q4 2018 | -2.4% | — | — | |
| Q1 2018 | -8.1% | — | — | |
| Q4 2016 | +0.0% | — | — | |
| Q3 2016 | +0.0% | — | — | |
| Q2 2016 | -5.8% | — | — | |
| Q1 2016 | +2.2% | — | — | |
| Q4 2015 | -8.2% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro